French multinational pharmaceutical and healthcare company Sanofi announced a partnership with New York-based TrialSpark, which offers a technology-based model for drug development.
TrialSpark's tools aim for more efficient trial design, faster trial completion and higher quality trial data. It acquires clinical-stage drugs from pharmaceutical and biotech companies and develops them using its...
Biopharma giant Sanofi is setting its sights on AI for drug discovery, inking a deal worth more than $100 million with tech company Exscientia.
As part of the deal, Exscientia is eligible for as much as $5.2 billion in payments for clinical development, regulatory and commercial milestones.
The deal will revolve around the development of up to 15 novel small molecule candidates in oncology and...
SELF-MANAGEMENT PLATFORM FOR IBD PATIENTS
Social purpose company, Ampersand Health has announced its partnership with Worcestershire Acute Hospitals NHS trust to roll out the inflammatory bowel disease (IBD) platform My IBD Care.
The initiative supports patients living with Crohn's disease and Ulcerative colitis and facilitates remote monitoring and communications between these patients and...
insitro and Exscientia, two platforms using artificial intelligence to drive the discovery of new drugs, announced this morning the raise of $143 million and $60 million, respectively, from investors.
insitro's oversubscribed Series B round was headed by Andreessen Horowitz, and joined by new backers Canada Pension Plan Investment Board, T. Rowe Price Associates, BlackRock, Casdin Capital, HOF...
German pharma giant Bayer and British biotech firm Exscientia have announced a three-year partnership focused on the use of Artificial Intelligence in cardiovascular and oncology drug discovery.
The collaboration will initially see the companies work on three early-stage research projects, combining Bayer’s data and drug discovery capabilities and Exscientia’s Centaur Chemist platform.
According...
